

Fourth Quarter 2023 Supplemental Financial Information

February 15, 2024

labcorp

Cautionary Statement Regarding Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2024 guidance and related assumptions, (ii) the recently completed spin-off of the company's Clinical Development and Commercialization Services business, now Fortrea Holdings Inc.; (iii) the impact of various factors on operating and financial results, including the impact of the COVID-19 pandemic on the company's businesses, operating results, cash flows and/or financial condition, as well as global economic and market conditions, (iv) future business strategies, (v) expected savings, benefits and synergies from the LaunchPad initiative and from acquisitions and other strategic transactions and partnerships, and (vi) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation, (i) the failure to receive tax-free treatment with respect to the spin-off for U.S. federal income purposes; (ii) potential difficulties with employee retention; (iii) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (iv) changes in government regulations, including healthcare reform; (v) customer purchasing decisions, including changes in payer regulations or policies; (vi) other adverse actions of governmental and third-party payers; (vii) changes in testing guidelines or recommendations; (viii) federal, state, and local government responses to the COVID-19 pandemic; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) the impact of changes in laws and regulations applicable to the company; (xiii) failure to maintain or develop customer relationships; (xiv) the company's ability to develop or acquire new products and adapt to technological changes; (xv) failure in information technology, systems, or data security; (xvi) the impact of potential losses under repurchase agreements; (xvii) adverse weather conditions; (xviii) the number of revenue days in a financial period; (xix) employee relations; (xx) personnel costs; (xxi) inflation; (xxii) increased competition; and (xxiii) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this presentation should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

Use of Adjusted Measures

The company has provided in this presentation and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EBITDA, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise “special items” used for certain adjusted financial information are included in the tables accompanying this presentation.

Fourth Quarter Consolidated Results

(Dollars in Millions, Except Per Share Data)

	<u>4Q23</u>	<u>4Q22</u>	<u>% Change</u>
Revenue	\$3,033.3	\$2,929.8	3.5% ⁽²⁾
Adjusted Operating Income ⁽¹⁾	\$394.9	\$412.6	(4.3%)
<i>Adjusted Operating Margin</i>	<i>13.0%</i>	<i>14.1%</i>	<i>(110 bps)</i>
Adjusted EPS ⁽¹⁾	\$3.30	\$3.05	8.2%
Operating Cash Flow from Continuing Operations	\$579.6	\$607.2	(4.5%)
Less: Capital Expenditures	<u>(\$165.4)</u>	<u>(\$99.1)</u>	66.9%
Free Cash Flow from Continuing Operations	\$414.2	\$508.1	(18.5%)

(1) Adjusted operating income and Adjusted EPS exclude amortization, restructuring charges, special items and impairments. See reconciliation of non-GAAP Financial Measures on slides 17-21.

(2) The increase was due to organic revenue of 1.5%, acquisitions, net of divestitures of 1.4%, and foreign currency translation of 0.7%. The 1.5% increase in organic revenue was driven by a 5.0% increase in the company's organic Base Business, partially offset by a (3.5%) decrease in COVID-19 PCR and antibody testing (COVID-19 Testing). Base Business includes Labcorp's operations except for COVID-19 Testing.

Full Year Consolidated Results

(Dollars in Millions, Except Per Share Data)

	<u>Year Ended 12/31/23</u>	<u>Year Ended 12/31/22</u>	<u>% Change</u>
Revenue	\$12,161.6	\$11,863.9	2.5% ⁽²⁾
Adjusted Operating Income ⁽¹⁾	\$1,714.9	\$2,172.6	(21.1%)
<i>Adjusted Operating Margin</i>	<i>14.1%</i>	<i>18.3%</i>	<i>(420 bps)</i>
Adjusted EPS ⁽¹⁾	\$13.56	\$16.66	(18.6%)
Operating Cash Flow from Continuing Operations	\$1,202.3	\$1,764.8	(31.9%)
Less: Capital Expenditures	<u>(\$453.6)</u>	<u>(\$429.3)</u>	(5.7%)
Free Cash Flow from Continuing Operations	\$748.7	\$1,335.5	(43.9%)

(1) Adjusted operating income and Adjusted EPS exclude amortization, restructuring charges, special items and impairments. See reconciliation of non-GAAP Financial Measures on slides 17-21.

(2) The increase was due to acquisitions net of divestitures of 1.7%, organic revenue of 0.6%, and favorable foreign currency translation of 0.2%. The 0.6% increase in organic revenue was due to an 8.7% increase in the Company's organic Base Business, partially offset by an (8.1%) decrease in COVID-19 Testing.

Fourth Quarter Adjusted Segment Results

(Dollars in Millions)

	<u>4Q23</u>	<u>4Q22</u>	<u>% Change</u>
Revenue			
Diagnostics Laboratories	\$2,346.9	\$2,286.4	2.6%
Biopharma Laboratory Services	\$694.8	\$648.8	7.1%
Total Revenue ⁽¹⁾	\$3,033.3	\$2,929.8	3.5%
Adjusted Operating Income ⁽²⁾			
Diagnostics Laboratories	\$353.7	\$387.0	(8.6%)
<i>Adjusted Operating Margin</i>	<i>15.1%</i>	<i>16.9%</i>	<i>(190 bps)</i>
Biopharma Laboratory Services	\$109.0	\$95.2	14.5%
<i>Adjusted Operating Margin</i>	<i>15.7%</i>	<i>14.7%</i>	<i>100 bps</i>
Unallocated Corporate Expense	(\$67.8)	(\$69.6)	(2.6%)
Total Adjusted Operating Income	\$394.9	\$412.6	(4.3%)
<i>Total Adjusted Operating Margin</i>	<i>13.0%</i>	<i>14.1%</i>	<i>(110 bps)</i>

(1) Consolidated revenues and segment adjusted operating income are presented net of intersegment transaction eliminations and other amounts not used in determining segment performance.

(2) Adjusted operating income excludes amortization, restructuring charges, and special items. See Reconciliation of Non-GAAP Financial Measures on slides 17-21.

Full Year Adjusted Segment Results

(Dollars in Millions)

	<u>Year Ended 12/31/23</u>	<u>Year Ended 12/31/22</u>	<u>% Change</u>
Revenue			
Diagnostics Laboratories	\$9,415.1	\$9,203.5	2.3%
Biopharma Laboratory Services	\$2,774.2	\$2,697.3	2.9%
Total Revenue ⁽¹⁾	\$12,161.6	\$11,863.9	2.5%
Adjusted Operating Income ⁽²⁾			
Diagnostics Laboratories	\$1,591.3	\$2,025.5	(21.4%)
<i>Adjusted Operating Margin</i>	<i>16.9%</i>	<i>22.0%</i>	<i>(510 bps)</i>
Biopharma Laboratory Services	\$396.3	\$389.1	1.8%
<i>Adjusted Operating Margin</i>	<i>14.3%</i>	<i>14.4%</i>	<i>(10 bps)</i>
Unallocated Corporate Expense	(\$272.7)	(\$242.0)	12.7%
Total Adjusted Operating Income	\$1,714.9	\$2,172.6	(21.1%)
<i>Total Adjusted Operating Margin</i>	<i>14.1%</i>	<i>18.3%</i>	<i>(420 bps)</i>

(1) Consolidated revenues and segment adjusted operating income are presented net of intersegment transaction eliminations and other amounts not used in determining segment performance.

(2) Adjusted operating income excludes amortization, restructuring charges, and special items. See Reconciliation of Non-GAAP Financial Measures on slides 17-21.

Fourth Quarter Adjusted Segment Results vs. 2019

(Dollars in Millions)

	<u>4Q23</u>	<u>4Q19</u>	<u>CAGR</u>
Revenue			
Diagnostics Laboratories Total	\$2,346.9	\$1,757.8	7.5%
Base Business - Revenue	\$2,308.8	\$1,757.8	7.1%
Base Business - Volume			2.3%
Base Business - Price/Mix			4.8%
Biopharma Laboratory Services Total	<u>\$694.8</u>	<u>\$555.3</u>	5.8%
Total Revenue ⁽¹⁾	\$3,033.3	\$2,307.1	7.1%

(1) Consolidated revenue is presented net of intersegment transaction eliminations and other amounts not used in determining segment performance. Base Business includes Labcorp's operations except for COVID-19 Testing.

Full Year Adjusted Segment Results vs. 2019

(Dollars in Millions)

	<u>Year Ended 12/31/23</u>	<u>Year Ended 12/31/19</u>	<u>CAGR</u>
Revenue			
Diagnostics Laboratories Total	\$9,415.1	\$6,999.9	7.7%
Base Business - Revenue	\$9,232.4	\$6,999.9	7.2%
Base Business - Volume			2.4%
Base Business - Price/Mix			4.8%
Biopharma Laboratory Services Total	<u>\$2,774.2</u>	<u>\$2,098.0</u>	7.2%
Total Revenue ⁽¹⁾	\$12,161.6	\$9,074.8	7.6%

(1) Consolidated revenue is presented net of intersegment transaction eliminations and other amounts not used in determining segment performance. Base Business includes Labcorp's operations except for COVID-19 Testing.

Select Financial Metrics

(Dollars in Millions)

	<u>4Q22</u>	<u>1Q23</u>	<u>2Q23</u>	<u>3Q23</u>	<u>4Q23</u>
Total Depreciation ⁽¹⁾	\$91.2	\$88.8	\$91.3	\$90.4	\$87.2
Total Amortization ⁽²⁾	\$44.7	\$53.4	\$51.5	\$55.7	\$59.2
Total Adjusted EBITDA ⁽¹⁾⁽³⁾	\$503.6	\$539.3	\$543.5	\$515.5	\$482.2
Total Debt to Last Twelve Months Adjusted EBITDA ⁽³⁾	1.9x	2.4x	2.6x	2.7x	2.5x
Total Net Debt to Last Twelve Months Adjusted EBITDA ⁽³⁾⁽⁴⁾	1.8x	2.3x	1.7x	2.3x	2.3x

(1) Depreciation and Adjusted EBITDA have been recast for 1Q23 (-3.4), 2Q23 (-2.7), and 3Q23 (+0.2).

(2) Excludes amortization of deferred financing fees.

(3) Adjusted EBITDA excludes restructuring charges and special items. See reconciliation on slide 17.

(4) Net debt equals total debt less cash and cash equivalents.

Biopharma Laboratory Services: Select Financial Metrics⁽¹⁾


Trailing Twelve Month (TTM) Results		
	Net Orders	Net Book-to-Bill
TTM Ending December 31, 2023	\$2.89 billion	1.04x
TTM Ending September 30, 2023	\$3.05 billion	1.12x
TTM Ending June 30, 2023	\$3.30 billion	1.23x
TTM Ending March 31, 2023	\$3.41 billion	1.28x
TTM Ending December 31, 2022	\$3.65 billion	1.35x

	Backlog	Estimated revenue expected to convert from backlog in the next twelve months
As of December 31, 2023	\$8.25 billion	\$2.47 billion
As of September 30, 2023	\$7.79 billion	\$2.41 billion
As of June 30, 2023	\$7.96 billion	\$2.46 billion
As of March 31, 2023	\$7.89 billion	\$2.40 billion
As of December 31, 2022	\$7.87 billion	\$2.41 billion


(1) Results shown include the impact from cancellations and foreign currency translation.

Fourth Quarter 2023 Revenue Distribution

Segment Distribution



Geographic Distribution



(1) Revenues recognized in over 10 currencies; the largest foreign currency accounts for less than 10% of total revenue.

Fourth Quarter 2023 Foreign Exchange Impact to Revenue⁽¹⁾ (Dollars in Millions)

	<u>Dollars</u>	<u>Year over Year % Growth</u>
<u>Consolidated</u>		
Revenues, as Reported	\$3,033	3.5%
Foreign Exchange Impact	(\$19)	(0.7%)
Revenues, Constant Currency	\$3,014	2.9%
<u>Diagnostics Laboratories</u>		
Revenues, as Reported	\$2,347	2.6%
Foreign Exchange Impact	\$1	0.0%
Revenues, Constant Currency	\$2,348	2.7%
<u>Biopharma Laboratory Services</u>		
Revenues, as Reported	\$695	7.1%
Foreign Exchange Impact	(\$20)	(3.1%)
Revenues, Constant Currency	\$675	4.0%

(1) May not foot due to rounding.

Full Year 2023 Foreign Exchange Impact to Revenue⁽¹⁾ (Dollars in Millions)

	<u>Dollars</u>	<u>Year over Year % Growth</u>
<u>Consolidated</u>		
Revenues, as Reported	\$12,162	2.5%
Foreign Exchange Impact	(\$25)	(0.2%)
Revenues, Constant Currency	\$12,137	2.3%
<u>Diagnostics Laboratories</u>		
Revenues, as Reported	\$9,415	2.3%
Foreign Exchange Impact	\$15	0.2%
Revenues, Constant Currency	\$9,431	2.5%
<u>Biopharma Laboratory Services</u>		
Revenues, as Reported	\$2,774	2.9%
Foreign Exchange Impact	(\$40)	(1.5%)
Revenues, Constant Currency	\$2,734	1.4%

(1) May not foot due to rounding.

Diagnostics Laboratories Price / Mix & Days

Revenue breakdown by Volume and Price / Mix								
Year over Year % Change	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023
Revenue ⁽¹⁾	(11.0%)	(4.7%)	(15.7%)	(12.8%)	(2.9%)	3.8%	6.2%	2.6%
Volume (in requisitions) ⁽²⁾	(5.0%)	(2.7%)	(10.3%)	(11.8%)	(3.3%)	1.4%	2.3%	2.4%
Price / mix ⁽³⁾	(6.0%)	(2.0%)	(5.4%)	(1.0%)	0.4%	2.4%	3.9%	0.2%

Days in 2023 Versus 2022 ⁽⁴⁾					
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Full Year ⁽⁵⁾
Revenue Day Variance	+0.75 Day	—	- 0.25 Day	- 0.50 Day	—
Payroll Day Variance	+1.00 Day	—	-1.00 Day	—	—

(1) Revenue variance percent: YOY change in revenue divided by prior year revenue.

(2) Volume (in requisitions) variance percent: YOY change in volume divided by prior year volume.

(3) Price / mix percent: Calculated as revenue variance percent, less volume (in requisitions) variance percent.

(4) Day variances are rounded to the nearest quarter day.

(5) May not foot due to rounding.

2024 Financial Guidance

(Dollars in billions, except per share data)

	Full Year Results	2024 Guidance		2024 Guidance	
	(in Dollars)	(in Dollars)		(% Versus 2023 Results)	
	<u>2023</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>
Revenue					
Labcorp Enterprise ⁽¹⁾⁽²⁾	\$12.16	\$12.73	\$12.95	4.7%	6.5%
Diagnostics Laboratories ⁽³⁾	\$9.42	\$9.72	\$9.87	3.2%	4.8%
Biopharma Laboratory Services ⁽⁴⁾	\$2.77	\$2.93	\$2.98	5.5%	7.5%
Adjusted EPS	\$13.56	\$14.30	\$15.40	5.5%	13.6%
Free Cash Flow from Cont. Ops ⁽⁵⁾	\$0.89	\$1.00	\$1.15	12.6%	29.5%

(1) 2024 Guidance percent changes as compared to 2023 results includes an impact from foreign currency translation of 0.6%.

(2) Enterprise level revenue is presented net of intersegment transaction eliminations.

(3) 2024 Guidance percent changes as compared to 2023 results includes an impact from foreign currency translation of 0.1%.

(4) 2024 Guidance percent changes as compared to 2023 results includes an impact from foreign currency translation of 2.2%.

(5) Free Cash Flow from continuing operations excluding spin-related items.

Additional Quarterly Business Segment Information (Dollars in Millions)

	2019				2020				2021				2022				2023				Q4'19 - Q4'23	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	CAGR	
Diagnostics Laboratories Revenue																						
Routine vs. Esoteric Mix Base Business:																						
Routine	59.4%	58.8%	58.8%	58.6%	58.6%	60.2%	61.2%	60.5%	60.7%	60.3%	60.1%	59.6%	59.9%	58.8%	59.1%	62.3%	62.5%	61.8%	61.3%	61.5%		
Esoteric	40.6%	41.2%	41.2%	41.4%	41.4%	39.8%	38.8%	39.5%	39.3%	39.7%	39.9%	40.4%	40.1%	41.2%	40.9%	37.7%	37.5%	38.2%	38.7%	38.5%		
Payer Mix Base Business:																						
Clients	27.9%	27.9%	27.8%	29.7%	28.2%	28.6%	29.0%	31.3%	28.9%	28.6%	30.2%	29.1%	28.0%	29.0%	29.5%	34.2%	32.0%	32.0%	31.1%	31.9%		
Patients	12.7%	12.6%	13.2%	12.8%	12.7%	12.8%	12.3%	11.7%	12.8%	14.1%	13.4%	11.8%	10.2%	12.8%	11.4%	10.0%	12.5%	13.0%	12.0%	12.4%		
Medicare and Medicaid	13.9%	13.7%	13.7%	13.8%	13.0%	13.1%	12.9%	12.4%	12.1%	11.7%	11.2%	11.5%	11.0%	11.0%	10.7%	10.2%	10.2%	10.1%	10.2%	10.1%		
Third Party	45.5%	45.7%	45.2%	43.7%	46.1%	45.6%	45.9%	44.6%	46.2%	45.5%	45.1%	47.5%	50.8%	47.2%	48.5%	45.7%	45.3%	44.9%	46.8%	45.5%		
Biopharma Laboratory Services																						
Quarterly Book-to-Bill	1.12	1.24	1.18	1.08	1.39	1.55	1.47	1.36	1.35	1.26	1.41	1.48	1.24	1.26	1.33	1.60	0.96	1.06	0.88	1.26		
Quarterly Net Orders	546.5	634.8	643.5	600.0	758.4	782.4	891.0	947.1	964.6	926.5	997.6	1,050.3	871.9	853.0	884.3	1,036.3	637.1	742.8	635.0	878.3		
Business Unit Revenue:																						
Early Development Research Labs	137.7	154.2	181.3	184.2	184.1	179.9	191.6	204.4	204.6	216.2	218.4	220.5	226.8	243.4	226.3	218.1	207.9	225.4	239.3	213.2	3.7%	
Central Laboratories	349.1	357.4	363.0	371.1	360.0	312.1	368.5	435.8	482.6	508.1	487.8	486.6	477.4	434.5	440.0	430.7	453.4	473.6	479.8	481.6	6.7%	
Segment Revenue Base Business	486.8	511.6	544.3	555.3	544.1	492.1	560.1	640.2	687.2	724.3	706.2	707.0	704.2	677.9	666.4	648.8	661.3	699.0	719.1	694.8	5.8%	
COVID-19 Testing	—	—	—	—	—	12.8	44.2	56.3	24.8	9.3	1.1	0.7	—	—	—	—	—	—	—	—	—	
Biopharma Laboratory Services Revenue	486.8	511.6	544.3	555.3	544.1	504.9	604.3	696.5	712.0	733.6	707.3	707.7	704.2	677.9	666.4	648.8	661.3	699.0	719.1	694.8	—	

Reconciliation of Non-GAAP Financial Measures – Adjusted EBITDA (Dollars in Millions)

	4Q22	1Q23	2Q23	3Q23	4Q23
Operating Income	\$28.6	\$329.8	\$266.3	\$252.3	(\$122.8)
Add:					
Restructuring and special charges	8.9	7.5	15.8	7.5	18.3
Goodwill and other asset impairments	260.6	2.2	—	10.2	333.8
Other special charges ⁽¹⁾	46.7	34.1	68.2	98.2	106.4
Depreciation ⁽²⁾	91.2	88.8	91.3	90.4	87.2
Amortization	44.7	53.4	51.5	55.7	59.2
Equity method income, net	(1.1)	(0.6)	1.9	(0.3)	0.1
EBITDA adjustments to equity method income, net	0.9	1.1	2.0	1.5	—
CDCS not included in Discontinued Operations	23.1	23.0	46.5	—	—
Adjusted EBITDA ⁽²⁾	503.6	539.3	543.5	515.5	482.2

⁽¹⁾ Other special charges represent the summation of the adjustments that impacted operating income excluding Restructuring and special charges, Goodwill and other asset impairments, and Amortization.

⁽²⁾ Depreciation and Adjusted EBITDA have been recast for 1Q23 (-3.4), 2Q23 (-2.7), and 3Q23 (+0.2).

Reconciliation of Non-GAAP Income Statement (Dollars in Millions, Except Per Share Data)

	GAAP		Non-GAAP	
	Three Months Ended December 31,		Three Months Ended December 31,	
	2023	2022	2023	2022
Revenues	\$ 3,033.3	\$ 2,929.8	\$ 3,033.3	\$ 2,929.8
Cost of revenues	2,211.9	2,131.7	2,171.1	2,089.4
Gross profit	821.4	798.1	862.2	840.4
Selling, general and administrative expenses	532.9	455.4	467.3	427.8
Amortization of intangibles and other assets	59.2	44.7		
Restructuring and other charges	18.3	9.0		
Goodwill and other asset impairments	333.8	260.5		
Operating income	(122.8)	28.5	394.9	412.6
Other income (expense):				
Interest expense	(48.8)	(49.1)	(48.8)	(49.2)
Investment income	6.2	1.3	6.2	1.8
Equity method income, net	0.1	(1.1)	0.1	(1.2)
Other, net	18.2	30.6	(1.8)	0.3
Earnings from continuing operations before income taxes	(147.1)	10.2	350.6	364.3
Provision (benefit) for income taxes	19.7	(26.9)	68.2	92.5
Earnings from continuing operations	(166.8)	37.1	282.4	271.8
Earnings from discontinued operations, net of tax	—	39.3	—	—
Net earnings	(166.8)	76.4	282.4	271.8
Less: Net earnings (loss) attributable to the noncontrolling interest	(0.3)	(0.3)	(0.3)	(0.3)
Net earnings attributable to LCAH	<u>\$ (167.1)</u>	<u>\$ 76.1</u>	<u>\$ 282.1</u>	<u>\$ 271.5</u>
Diluted earnings per common share:				
Diluted earnings per common share continuing operations	\$ (1.95)	\$ 0.42	\$ 3.30	\$ 3.05
Diluted earnings per common share discontinued operations	\$ —	\$ 0.44	\$ —	\$ —
Diluted earnings per common share	\$ (1.95)	\$ 0.86	\$ 3.30	\$ 3.05
Weighted average diluted shares outstanding	85.5	89.0	85.5	89.0

Reconciliation of Non-GAAP Income Statement (Dollars in Millions, Except Per Share Data)

	GAAP		Non-GAAP	
	Twelve Months Ended December 31,		Twelve Months Ended December 31,	
	2023	2022	2023	2022
Revenues	\$ 12,161.6	\$ 11,863.9	\$ 12,161.6	\$ 11,863.9
Cost of revenues	8,796.7	8,155.0	8,636.6	8,036.7
Gross profit	3,364.9	3,708.9	3,525.0	3,827.2
Selling, general and administrative expenses	2,021.4	1,763.1	1,810.1	1,654.6
Amortization of intangibles and other assets	219.8	193.6		
Restructuring and other charges	49.1	54.0		
Goodwill and other asset impairments	349.0	261.7		
Operating income	725.6	1,436.5	1,714.9	2,172.6
Other income (expense):				
Interest expense	(199.6)	(179.8)	(200.1)	(180.3)
Investment income	28.8	7.5	27.6	8.9
Equity method income, net	(1.4)	5.4	1.3	5.4
Other, net	15.5	(32.2)	(10.7)	(12.4)
Earnings from continuing operations before income taxes	568.9	1,237.4	1,533.0	1,994.2
Provision for income taxes	188.5	233.9	344.1	467.2
Earnings from continuing operations	380.4	1,003.5	1,188.9	1,527.0
Earnings from discontinued operations, net of tax	38.8	277.1	—	—
Net earnings	419.2	1,280.6	1,188.9	1,527.0
Less: Net earnings (loss) attributable to the noncontrolling interest	(1.2)	(1.5)	(1.2)	(1.4)
Net earnings attributable to LCAH	\$ 418.0	\$ 1,279.1	\$ 1,187.7	\$ 1,525.6
Diluted earnings per common share:				
Diluted earnings per common share continuing operations	\$ 4.33	\$ 10.94	\$ 13.56	\$ 16.66
Diluted earnings per common share discontinued operations	\$ 0.44	\$ 3.03	\$ —	\$ —
Diluted earnings per common share	\$ 4.77	\$ 13.97	\$ 13.56	\$ 16.66
Weighted average diluted shares outstanding	87.6	91.6	87.6	91.6

Reconciliation of Non-GAAP Financial Measures⁽¹⁾

(Dollars in Millions, Except Per Share Data)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2023	2022	2023	2022
<u>Adjusted Operating Income</u>				
Operating Income	\$ (122.8)	\$ 28.5	\$ 725.6	\$ 1,436.5
Amortization of intangibles and other assets ^(a)	59.2	44.7	219.8	193.6
Restructuring and other charges ^(b)	18.3	9.0	49.1	54.0
Asset impairments ^(c)	333.8	260.5	349.0	261.7
Acquisition and disposition-related costs ^(d)	16.5	31.8	56.0	63.7
Spin off transaction costs ^(e)	22.6	3.5	94.1	6.5
COVID-19 related costs ^(f)	20.7	9.9	59.6	27.1
Other ^(g)	23.2	1.6	46.1	36.6
TSA reimbursement (h)	23.4	—	46.1	—
CDCS not included in discontinued operations (i)	—	23.1	69.5	92.9
Adjusted operating income	<u>\$ 394.9</u>	<u>\$ 412.6</u>	<u>\$ 1,714.9</u>	<u>\$ 2,172.6</u>
<u>Adjusted Net Income</u>				
Net Income	\$ (167.1)	\$ 76.1	\$ 418.0	\$ 1,279.1
Impact of adjustments to operating income	517.7	361.0	919.8	643.2
(Gains) / losses on venture fund investments, net ^(j)	3.4	0.7	4.8	12.0
TSA reimbursement ^(h)	(23.4)	—	(46.1)	—
Pension settlement ^(k)	—	(0.9)	10.8	3.1
Other	—	(1.8)	0.5	(2.1)
Income tax impact of adjustments ^(l)	(48.5)	(119.5)	(155.7)	(233.3)
Earnings from discontinued operations, net of tax ⁽ⁱ⁾	—	(39.3)	(38.8)	(277.1)
CDCS not included in discontinued operations ⁽ⁱ⁾	—	(4.8)	74.4	100.7
Adjusted net income	<u>\$ 282.1</u>	<u>\$ 271.5</u>	<u>\$ 1,187.7</u>	<u>\$ 1,525.6</u>
Weighted average diluted shares outstanding	85.5	89.0	87.6	91.6
Adjusted net income per share	\$ 3.30	\$ 3.05	\$ 13.56	\$ 16.66

Reconciliation of Non-GAAP Financial Measures – Footnotes

- (a) Amortization of intangible assets acquired as part of business acquisitions.
- (b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities within the organization in connection with our LaunchPad initiatives, the Fortrea spin, and acquisitions or dispositions of businesses by the company.
- (c) Asset impairments relate primarily to goodwill within the early development reporting unit and other intangible assets deemed to be realizable.
- (d) Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, and other integration or disposition related activities.
- (e) The company incurred various costs to prepare for the spin-off of Fortrea and reorganization of the remaining Labcorp business.
- (f) Costs of incremental operating expenses incurred as a result of the COVID-19 pandemic.
- (g) Represents various non-operational items including litigation, launchpad system implementation costs and other miscellaneous adjustments.
- (h) Represents transition services fees charged to Fortrea related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income.
- (i) These adjustments remove the impact of the CDCS business that was distributed to Labcorp shareholders as part of a tax-free spin on June 30, 2023.
- (j) The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.
- (k) The company incurred a charge related to the US pension plan due to settlement of certain obligations to retired employees.
- (l) Income tax impact of adjustments calculated based on the tax rate applicable to each item.